Viewing Study NCT02198651

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:53 PM
Ignite Modification Date: 2026-01-26 @ 7:28 PM
Study NCT ID: NCT02198651
Status: COMPLETED
Last Update Posted: 2019-06-25
First Post: 2014-07-22
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
Sponsor: AbbVie
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Rheumatoid Arthritis View
None Musculoskeletal and Connective Tissue Diseases View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Rheumatoid Arthritis View
None Adalimumab View
None Taper View
None Flare View
None Arthritis View
None Anti-rheumatic drugs View
None Remission View
None Magnetic Resonance Imaging View
None Ultrasound View
None Biomarker View
None Drug Level View
None Reduced dose View